StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Stock analysts at StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Friday. The firm set a “hold” rating on the stock.

Several other analysts have also recently weighed in on the stock. Lake Street Capital reduced their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. HC Wainwright decreased their price objective on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Trading Down 10.5 %

Shares of EKSO stock opened at $0.57 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. Ekso Bionics has a fifty-two week low of $0.50 and a fifty-two week high of $3.13. The stock has a market capitalization of $12.56 million, a P/E ratio of -0.88 and a beta of 1.43. The company has a 50 day moving average price of $0.85 and a 200 day moving average price of $1.03.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter last year, the business posted ($0.24) earnings per share. Equities research analysts predict that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.